#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Colorectal cancer screening in the Czech Republic – past, present and future


Authors: Š. Suchánek 1,2;  M. Ambrožová 3,4;  T. Grega 1,2;  R. Chloupková 3,4;  K. Hejcmanová 3,4;  O. Ngo 3,4;  O. Májek 3,4;  K. Hejduk 3,4;  L. Dušek 3,4;  M. Zavoral 1,2
Authors place of work: Interní klinika 1. LF UK a ÚVN Praha 1;  Ústav gastrointestinální onkologie 1. LF UK a ÚVN Praha 2;  Národní screeningové centrum, Ústav zdravotnických informací a statistiky České republiky, Praha 3;  Institut biostatistiky a analýz, LF MU, Brno 4
Published in the journal: Gastroent Hepatol 2024; 78(5): 378-387
Category:
doi: https://doi.org/10.48095/ccgh2024378

Summary

The National Colorectal Cancer Screening Program has been conducted in the Czech Republic since 2000 and serves as an example of interdisciplinary collaboration. Specialists from gastroenterology, general practice, gynecology, and clinical biochemistry are involved in the program. It is based on two primary methods: the screening fecal immunochemical test for occult bleeding (iFOBT, FIT) and preventive colonoscopy (FOBT-positive colonoscopy and screening colonoscopy). The program‘s effectiveness is evidenced by the high number of detected colorectal precancerous and malignant lesions. Between 2006 and 2023, a total of 531,362 preventive colonoscopies were performed, diagnosing 202,575 patients with adenomas (38.1%) and 14,473 patients with cancers (2.7%). Program quality is monitored by indicators focused on both organization (target population coverage) and screening methods. Coverage with screening tests in a 2-year interval has consistently ranged around 30%, except between 2020 and 2021 during the COVID-19 pandemic (27%), reaching 30.0% in 2023. Non-screening tests also affect epidemiological indicators, with total coverage by all relevant methods in a 2-year interval in 2023 amounting to 37.5%. Colonoscopies are evaluated using six parameters (number of examinations, bowel preparation quality, total colonoscopies, and adenoma detection rate in total, in both women and men). In 2023, 72% of screening colonoscopy centers met all of these indicators. FOBT analyzers now must have the regular external quality assessment (EQA), which should help stabilize test positivity, standing at 9.1% in 2023. Thanks to the National Colorectal Cancer Screening Program, favorable epidemiological trends have been observed, with a 32.3% decrease in incidence and a 47.8% decrease in mortality between 2000 and 2022. The future of the program lies in its further optimization, with a goal of both increasing coverage of the target population by examination and quality improvement, ensuring the program’s feasibility and efficiency.

Keywords:

colorectal cancer – adenoma – screening – colonoscopy – fecal immunochemical test – quality indicators


Zdroje
1. Ferlay J, Ervik M, Lam F et al. Global Cancer Observatory: Cancer Today (2024). Lyon, France: International Agency for Research on Cancer. 2024 [online]. Dostupné z: https: //gco.iarc.who.int/today.
2. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita, verze 7.0. 2007 [online]. Dostupné z: http: //www.svod.cz.
3. Ministerstvo zdravotnictví České republiky. 2009 [online]. Dostupné z: https: //mzd.gov.cz/ vestnik/vestnik-c-1-2009/.
4. Ministerstvo zdravotnictví České republiky. 2020 [online]. Dostupné z: https: //mzd.gov.cz/ vestnik/vestnik-c-9-2020/.
5. Ministerstvo zdravotnictví České republiky. 2021 [online]. Dostupné z: https: //mzd.gov.cz/vestnik/vestnik-c-14-2021/.
6. Ministerstvo zdravotnictví České republiky. 2023 [online]. Dostupné z: https: //mzd.gov.cz/vestnik/vestnik-11-2023/.
7. Falt P, Cyrany J, Kunovský L et al. Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii – aktualizované vydání 2024. Gastroenterol Hepatol 2024; 78 (3) 197–235. doi: 10.48095/ccgh2024197.
8. Falt P, Cyrany J, Kunovský L et al. Doporučené postupy České gastroenterologické společnosti ČLS JEP pro diagnostickou a terapeutickou koloskopii – aktualizované vydání 2024. 2024 [online]. Dostupné z: https: //www.cgs-cls.cz/doporucene-postupy-ceske-gastro- enterologicke-spolecnosti-cls-jep-pro-diagnostickou-a-terapeutickou-koloskopii-aktualizovane-vydani-2024/.
9. Seznam zdravotních výkonů. 2024 [online]. Dostupné z: https: //szv.mzcr.cz.
10. Segnan N, Patnick J, von Karsa L et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. Luxembourg: Publications Office of the European Union 2010.
11. Kaminski M F, Thomas-Gibson S, Bugajski M et al. Performance measures for lower gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. Endoscopy. 2017; 49 (4): 378–397. doi: 10.1055/s-0043-103411.
ORCID autorů
Š. Suchánek 0000-0003-3659-0252,
M. Ambrožová 0009-0002-3221-310X,
T. Grega 0000-0002-2490-8078,
R. Chloupková 0000-0002-4091-104X,
K. Hejcmanová 0000-0003-1385-7655,
O. Ngo 0000-0003-0589-8991,
O. Májek 0000-0002-0034-3084,
K. Hejduk 0000-0001-6215-4679,
L. Dušek 0000-0002-8589-4378,
M. Zavoral 0000-0001-7883-7431.
Doručeno/Submitted: 8. 10. 2024
Přijato/Accepted: 18. 10. 2024
Korespondenční autor
doc. MUDr. Štěpán Suchánek, Ph.D.
Interní klinika
1. LF UK a ÚVN Praha
U Vojenské nemocnice 1200
169 02 Praha 6
stepan.suchanek@uvn.cz
Štítky
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Článok vyšiel v časopise

Gastroenterology and Hepatology

Číslo 5

2024 Číslo 5
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#